TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02959021

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight loss intervention - self directed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss intervention - peer coach
Study: NCT04167631

Intervention type: RADIATION
Group type: OTHER
Intervention: Multi-parametric MRI
Description: Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
Study: NCT02712671

Intervention type: PROCEDURE
Intervention: Blood interferon gamma release assay
Description: Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).

Intervention type: PROCEDURE
Intervention: Tuberculin skin testing (TST)
Description: An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.

Intervention type: PROCEDURE
Intervention: Sputum induction for mycobacterial microscopy and culture
Description: Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.

Intervention type: OTHER
Intervention: Mycobacterium tuberculosis polymerase chain reaction testing
Description: Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.

Intervention type: PROCEDURE
Intervention: Spirometry
Description: Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
Study: NCT02057289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
Study: NCT01127217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine/losartan
Description: amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
Study: NCT05114694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early APM
Description: Early APM group were patients have knee syndrome within 3 to 6 months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: delayed APM
Description: delayed APM group recruit participants who received delayed APM surgery within 6 to 12 months
Study: NCT01108835

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive care programme
Description: Intervention group:~* Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~* Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~* Respiratory physician assessment and optimization of treatment~* Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~* Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries.
Study: NCT02882711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
Study: NCT00778284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
Study: NCT00184483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein's operation
Description: Lichtenstein's operation to repair primary unilateral inguinal hernia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene Hernia System
Description: Prolene Hernia System to repair primary unilateral inguinal hernia
Study: NCT04172493

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperspectral Endoscopy (HySE)
Description: Undergo hyperspectral endoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: White Light Endoscopy (WLE)
Description: Undergo white light endoscopy
Study: NCT04482829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jing-yan-kang Granule
Description: Jing-yuan-kang granule will be administered 6 days on and 1 days off for 12weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: PC chemotherapy and symptomatic treatment
Description: Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC chemotherapy and symptomatic treatment
Description: Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin. Pemetrexed disodium for injection 500 mg per square meter, intravenous drip on day 1 in each treatment cycle.~Cisplatin injection 75 mg per square meter, intravenous drip from day 1 to day 3 in each treatment cycle. One treatment cycle will be continued for 21 days and 4 cycles will be performed.~If necessary, symptomatic treatment will also be used.
Study: NCT02479516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Assessment Program Philippines (CHAP-P)
Study: NCT01909570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective single embryo transfer
Description: After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double embryo transfer
Description: After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
Study: NCT01914809

Intervention type: OTHER
Group type: OTHER
Intervention: samples blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: samples blood

Intervention type: OTHER
Group type: OTHER
Intervention: biopsy placentaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsy placentaire
Study: NCT00332332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: etanercept subcutaneous injection
Study: NCT02200939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioinductive implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioinductive implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical repair
Description: Surgical repair with commercially-available sutures/suture anchors.
Study: NCT01806740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
Study: NCT02261090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B: Pramipexole Slow release (SR) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C: Pramipexole Slow release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D: Pramipexole Slow release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E: Pramipexole Slow release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F: Pramipexole Slow release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation G: Pramipexole Slow release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H: Pramipexole Slow release tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole immediate release (IR) tablets
Study: NCT00753883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 20 mg/QD for 6 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin 20 mg/QD for 6 Weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg/QD for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg/QD for 8 weeks.
Study: NCT01332890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Study: NCT03053115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxin
Description: Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Controls will take placebo two hours after dinner
Study: NCT01257763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Microchannel Skin System
Description: A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
Study: NCT01332890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 3
Description: Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 5
Description: Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequence 6
Description: Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
Study: NCT02134210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Head-to-head comparison

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-0214
Study: NCT04551196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alternating Acetaminophen and Ibuprofen
Description: Subjects will alternate their post-operative acetaminophen and ibuprofen every 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Acetaminophen and Ibuprofen
Description: Subjects will take their post-operative acetaminophen and ibuprofen together every 6 hours.
Study: NCT02350920

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Committment Therapy (ACT)
Description: This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
Study: NCT01982877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Supports Intervention
Description: The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Control Intervention
Description: In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Control Intervention
Description: In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
Study: NCT02527837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrite
Description: Sodium nitrite, 240 micrograms/kg/hour for 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
Study: NCT03083392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment of chronic maxillary sinusitis using DIVA system
Description: chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic implant valve approach - DIVA system
Description: The DIVA system will be used to apply saline lavage to the maxillary sinus
Study: NCT02970032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Real time heparin dose adjustment
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard heparin dose
Description: Patients will be placed on heparin infusions per their surgeon's discretion.
Study: NCT02673905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Engineered Product
Description: Implantation of tissue engineered products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Engineered Product
Description: Implantation of tissue engineered products
Study: NCT00561444

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking 20 minutes to complete.
Study: NCT01086605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pixantrone dimaleate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pixantrone dimaleate
Description: Given IV
Study: NCT03601455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT03368885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal dietary diversity
Description: Counsel pregnant women for proper dietary intake and create awareness among family members and community to support her on maternal nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet diversity in complementary feeding
Description: Counsel mothers of children of 6-23 months on diet diversity in complementary feeding by demonstration during home-visits and seek support from father and family members
Study: NCT03601455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT00957931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Description: Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
Study: NCT03368885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive Breast Feeding
Description: Counselling on exclusive breast feeding among children under 6 months-Provide information to mothers of children of 3-6 months for exclusive breast feeding through home visits, and mothers meetings
Study: NCT00957931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Study: NCT04178538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation
Description: ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation
Description: ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL reconstruction with all inside technique
Description: Standard ACL reconstruction with all inside technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL reconstruction with all inside technique
Description: Standard ACL reconstruction with all inside technique
Study: NCT02409550

Intervention type: OTHER
Intervention: CARATKids Questionnaire
Study: NCT00720902

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draws
Description: Subjects will have serum cardiovascular markers assessed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draws
Description: Subjects will have serum cardiovascular markers assessed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone releasing hormone (GHRH) & arginine
Description: Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone releasing hormone (GHRH) & arginine
Description: Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid ultrasound
Description: Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid ultrasound
Description: Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial cell biopsy
Description: Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial cell biopsy
Description: Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
Study: NCT01879423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Dispersible/Chewable tablets 5mg*5
Description: Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Dispersible/Chewable tablets 5mg*5
Description: Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Compressed tablet 25mg
Description: Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Compressed tablet 25mg
Description: Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15